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MicroRNAs are important regulators of normal andmalignant hematopoiesis. A paper by Lu et al. in this issue
of Developmental Cell demonstrates how one microRNA, miR-150, plays a critical role in commitment of the
erythroid-megakaryocyte progenitor by modulating the level of the widely expressed transcription factor
MYB (or c-Myb).Lineage commitment during hematopoi-
etic development and differentiation is
highly dependent upon changes in gene
expression mediated by transcriptional
regulators. The unique expression of spe-
cific transcription factors or combinations
of factors can be the prime influence on
commitment, for example as is dictated
by the zinc-finger protein Th-POK in
determining a CD4+ fate on immature
CD4+CD8+ thymocytes. However, mech-
anisms involving alterations in the level
of activity of a particular regulator also
seem to be important (Rosenbauer et al.,
2005), and in addition to variations in the
transcription of its gene, this can involve
mRNA stability, protein translation, and al-
terations in protein activity brought about
by modification or degradation. Recently,
it has emerged that a commonly employed
mechanism for influencing the level of
protein expression during differentiation
utilizes small noncoding RNAs termed
microRNAs (miRNAs), which are a family
of 18-22 nt RNAs that can repress mRNA
translation or degrade mRNA. Approxi-
mately 150 miRNAs have been identified
in bone marrow, and although most of
them are also found in nonhematopoietic
tissues, several appear to be restricted
to the hematopoietic hierarchy (Chen
et al., 2004). Many of the widely distributed
miRNAs nevertheless exhibit variations in
their expression throughout hematopoi-
etic differentiation, a notable example be-
ing miR-150, which is highly upregulated
during the development of mature T and
B cells and is crucial for terminal stages
of differentiation (Xiao et al., 2007; Zhou
et al., 2007). Although individual miRNAs
have multiple potential target mRNAs, itappears that certain genes are central to
their action. miR-150 is also a good exam-
ple of the latter in that its top predicted
target is MYB (or c-Myb), a transcription
factor that has multiple roles throughout
the hematopoietic hierarchy, from stem
cells through progenitors to some stages
of specific lineage differentiation. In line
with MYB being a good potential target,
it was demonstrated that changes in
MYB associated with altered miR-150
expression account for at least some of
the phenotypic consequences in the lym-
phoid compartment (Xiao et al., 2007).
The paper by Lu et al. (2008) in this is-
sue of Developmental Cell takes the story
of the involvement of miRNAs in hemato-
poiesis a step further. By using a novel
technique for the analysis of miRNAs in
small numbers of cells, the authors define
the miRNA profile in highly purified pro-
genitors and their immediate committed
progeny. Their goal was to define how
erythroid and megakaryocytic commit-
ment from the common progenitor, the
MEP, is selectively controlled. Interest-
ingly, they found that miR-150 expression
varied as a feature of MEP commitment in
that the level was much higher in mega-
karyocytes compared with either MEPs
or erythroid cells. As in the lymphoid
studies, manipulation of the level of miR-
150 had a functional consequence, with
higher expression favoring differentiation
toward megakaryocytes at the expense
of erythropoiesis. Moreover, as in the
earlier studies, Lu et al. show that MYB
is a key target of miR-150 in bringing
about this effect on differentiation. These
observations could be interpreted as ef-
fects on differentiation postcommitmentDevelopmentalor the commitment event itself at the level
of the MEP. In previous studies, genetic
manipulations of MYB levels have shown
that it has direct effects on erythropoiesis,
one of which is promoting commitment of
erythroid progenitors (Vegiopoulos et al.,
2006). To date there is no evidence that
MYB has any direct effect on the progres-
sion of megakaryocytic differentiation.
This could suggest that miR-150 shifts
the erythroid/megakarocyte balance by
inhibiting erythropoiesis. However, the
experiments performed by Lu et al. sug-
gest that a major part of the effect of
miR-150/MYB is directly in the MEP, im-
plicating MYB as an active promoter of
erythroid commitment or a block to mega-
karyocyte commitment.
The importance of MYB as a key down-
stream target of miR-150 during the
commitment of MEPs agrees well with a
growing body of evidence that has impli-
cated this transcription factor in both ery-
throid and megakaryocytic differentiation
and has suggested that modulations in
its level, rather than just its presence or
absence, underlie its role. Both genetic
knockdown of MYB expression and
specific point mutations that affect the
protein’s function result in a phenotype
involving parts or all of the hematopoietic
hierarchy, with the common feature of
anemia and thrombocytosis (elevated
platelet levels) in the peripheral blood,
paralleled by perturbed erythropoiesis
and excess megakaryocytes in the bone
marrow (Emambokus et al., 2003; Carpi-
nelli et al., 2004; Sandberg et al., 2005).
Changes in miRNA expression have
been associated with a number of hema-
tological diseases. Interestingly, in theCell 14, June 2008 ª2008 Elsevier Inc. 815
Developmental Cell
Previewsmyeloproliferative disorder (MPD) polycy-
themia vera, in which erythropoiesis is
characteristically elevated, there is a sig-
nificant decline in the levels of miR-150
(Bruchova et al., 2007). This is clearly con-
sistent with the experimental observations
made by Lu et al., but it is also intriguing in
that it suggests that the miR-150/MYB
axis could be a critical factor in MPDs.
Indeed, the mouse models of reduced
MYB activity all demonstrate features of
MPD characterized by elevated platelet
numbers, and it can be speculated that
increased miR-150/decreased MYB ex-
pression may contribute to the disease
phenotype. Whether or not miR-150
and MYB are directly implicated in the
initiation or progression of such MPDs,
their impact on commitment nevertheless
suggests possible strategies for therapeu-
tic intervention.
Many questions remain regarding the
control of MEP commitment by miRNAs.
What other genes does miR-150 regu-
late? Do other miRNAs have a role, both
in MYB expression and that of other
targets? How are the miRNA levels them-
selves regulated? It will also be importantShooting the Mess
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The insulin-phosphoinositide 3-kinase
(PI3K) pathway regulates diverse pro-
cesses including glucose homeostasis,
survival, and growth. Aberrant regulation
of this pathway can lead to the develop-
ment of Type 2 diabetes or cancer; there-
fore, regulating PI3K signaling represents
an important element of metabolic control.
816 Developmental Cell 14, June 2008 ª2008to determine why MYB is a critical target
of miR-150; that is, what genes does it
regulate, especially if its role is one of
controlling commitment? Another impor-
tant step will be to determine how MYB
activity in the MEP and following lineage
commitment integrates with the many
transcriptional regulators that are already
known to be important for erythroid and/
or megakaryocytic gene expression (e.g.,
GATA-1, EKLF, STAT5, SCL, NF-E2, and
Fli1, to mention but a few). The answers
to these questions will require some so-
phisticated gene expression analysis of
purified MEPs undergoing conditional
alteration of MYB activity. With this infor-
mation in hand it will be interesting to
determine if other hematopoietic progen-
itors and stem cells, all of which express
MYB, are similarly regulated with respect
to their commitment toward specific dif-
ferentiated fates.
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RS-1) is targeted for ubiquitination
l. reveal that the E3 ubiquitin-ligase
zyme in the regulation of insulin
also acts negatively via a feedback loop
to inhibit IRS abundance (Figure 1),
thereby ensuring a limitation of PI3K
signaling (Harrington et al., 2004). IRS-1
inhibition occurs at both transcriptional
and posttranslational levels (Harrington
et al., 2005), including ubiquitin-media-
ted proteolysis by SOCS1/3-containing
